Advancing Antibiotic Use and Preventing Hearing Loss in Babies: Evidence-generation plan for Genedrive MT-RNR1 ID Kit

By Danélia Botes

August 14, 2023

NICE has recommended further evidence generation for the Genedrive MT-RNR1 ID Kit, a technology developed to detect a genetic variant that guides antibiotic use and prevents hearing loss in babies.

This plan outlines the gaps in evidence for the technology and the real-world data that needs to be collected for a future NICE review. The responsibility for data collection and analysis lies with the technology developer.

Support for evidence generation will be facilitated by the Office for Life Sciences, pending business case approval. This includes funding for evidence generation consortia, bringing together analytical partners, implementation sites, and developers.

Guidance on commissioning and procurement of the technology will be provided by NHS England, who is also developing a digital health technology policy framework.

After 3 years of evidence generation, the developer should submit the evidence to NICE for review and decision making on routine adoption in the NHS.

Reference url

Recent Posts

Cutaneous Malignant Melanoma Treatment

Forecasting Innovations in Cutaneous Malignant Melanoma Treatment in Sweden

“Shaping Melanoma Care: Insights for UV Safety Month”

🌟 Exciting Insights! Learn how system dynamics modelling shapes the future of cutaneous malignant melanoma care during UV Safety Month. Discover key strategies for better healthcare planning and patient outcomes. #SyenzaNews #UVSafetyMonth #HealthcarePlanning #MelanomaCare #PreventiveInterventions 🏥

skin cancer primary prevention

Enhancing Skin Cancer Prevention in a Primary Care Setting

🌞 Discover the latest strategies in skin cancer primary prevention! From innovative risk assessment tools to new technologies, learn how primary care can play a pivotal role in reducing skin cancer rates.
🩺👩‍⚕️👨‍⚕️ #SyenzaNews #Healthcare #SkinCancerPrevention #PrimaryCare #Innovation

Valvular heart disease in Saudi Arabia

Addressing Valvular Heart Disease in Saudi Arabia

#SyenzaNews 🚀 Valvular heart disease (VHD) is a growing concern in Saudi Arabia, especially among the ageing population.
Discover the current challenges and actionable recommendations to enhance VHD care.

Let’s work together to improve awareness, detection, and treatment! #Healthcare #Cardiology #SaudiArabia #HealthyAging 🌟

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.